山德士Sandoz 2025年第一季度财报-净销售额「瑞士证券交易所」（英文版）（28页）.pdf

1、Q1 2025 sales updateApril 30,20252This presentation contains forward-looking statements,which offer no guarantee with regard to future performance.These statements are made on the basis of managements views and assumptions regarding future events and business performance at the time the statements a

2、re made.They are subject to risks and uncertainties including,but not confined to,future global economic conditions,exchange rates,legal provisions,market conditions,activities by competitors and other factors outside of the control of Sandoz.Should one or more of these risks or uncertainties materi

3、alize or should underlying assumptions prove incorrect,actual outcomes may vary materially from those forecasted or expected.Each forward-looking statement speaks only as of the date of the particular statement,and Sandoz undertakes no obligation to publicly update or revise any forward-looking stat

4、ements,except as required by law.This presentation includes non-IFRS financial measures as defined by Sandoz.An explanation of non-IFRS measures can be found in the supplementary financial information of the 2024 Integrated Annual Report.Certain figures contained in this presentation,including finan

5、cial information presented in billions or millions,certain operating data and percentages describing financial information or market shares,have been subject to rounding.Dollar values and percentages may not agree to totals.Disclaimer1.Highlights&business update2.Net-sales performance&guidance3.Wrap

6、-upAgendaHighlights&business updateRichard SaynorChief Executive OfficerFull-year guidance confirmed51Growing track record of execution and performanceQ1 net sales in line with our expectationsFull-year impact of confirmed tariffs absorbed within guidance Double-digit biosimilar sales growth;further